About SeQure Dx
SeQure Dx is a company based in Waltham (United States) founded in 2020 by Ellen Sheets was acquired by MaxCyte in January 2025.. SeQure Dx has raised $22.29 million across 3 funding rounds from investors including MaxCyte, ARE and RiverVest Venture Partners. SeQure Dx offers products and services including ONE-seq, SAFER Detection, Guide Profiler, Electroporation Systems, and ATx System. SeQure Dx operates in a competitive market with competitors including Denali Therapeutics, Poseida Therapeutics, Castle Biosciences, Juno Therapeutics and Unity Biotechnology, among others.
- Headquarter Waltham, United States
- Founders Ellen Sheets
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of SeQure Dx
SeQure Dx offers a comprehensive portfolio of products and services, including ONE-seq, SAFER Detection, Guide Profiler, Electroporation Systems, and ATx System. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Variant-aware guide selection for therapeutic gene editing.
Efficient interrogation of DNA rearrangements in edited cells.
Computational aid for improved guide RNA selection in CRISPR.
Systems for cell transfection in therapy production.
Device for small to medium static electroporation processes.
Scalable electroporation for up to 20 billion cells.
Clinically validated flow-through electroporation device.
Tool for gram-scale protein production via electroporation.
Unlock access to complete
Sales and Marketing
2 people
Software Development Team
1 people
Leadership Team
1 people
Senior Team
1 people
Unlock access to complete
Funding Insights of SeQure Dx
SeQure Dx has successfully raised a total of $22.29M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $2.18 million completed in November 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series A — $2.2M
-
First Round
First Round
(03 Aug 2021)
- Investors Count 7
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2023 | Amount | Series A - SeQure Dx | Valuation |
investors |
|
| Jun, 2023 | Amount | Series A - SeQure Dx | Valuation |
investors |
|
| Aug, 2021 | Amount | Series A - SeQure Dx | Valuation | RiverVest Venture Partners , Mass General Brigham Ventures |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in SeQure Dx
SeQure Dx has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include MaxCyte, ARE and RiverVest Venture Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
Digitalis Ventures is engaged in health-focused investments.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by SeQure Dx
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - SeQure Dx
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Sequre Dx Comparisons
Competitors of SeQure Dx
SeQure Dx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Denali Therapeutics, Poseida Therapeutics, Castle Biosciences, Juno Therapeutics and Unity Biotechnology, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| domain | founded_year | HQ Location |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| domain | founded_year | HQ Location |
Precision diagnostic and prognostic tests are developed by Castle Biosciences.
|
|
| domain | founded_year | HQ Location |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for aging diseases are developed by targeting senescent cells.
|
|
| domain | founded_year | HQ Location |
Diagnostic services are provided through laboratories and radiology units.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Sequre Dx
Frequently Asked Questions about SeQure Dx
When was SeQure Dx founded?
SeQure Dx was founded in 2020 and raised its 1st funding round 1 year after it was founded.
Where is SeQure Dx located?
SeQure Dx is headquartered in Waltham, United States. It is registered at Waltham, Massachusetts, United States.
Is SeQure Dx a funded company?
SeQure Dx is a funded company, having raised a total of $22.29M across 3 funding rounds to date. The company's 1st funding round was a Series A of $17.5M, raised on Aug 03, 2021.
What does SeQure Dx do?
Developer of personalized diagnostics for gene-editing therapies. The companys technologies GUIDE-seq and ONE-seq enable the identification and confirmation of target sites for developing gene therapies.
Who are the top competitors of SeQure Dx?
SeQure Dx's top competitors include Juno Therapeutics, Poseida Therapeutics and Denali Therapeutics.
What products or services does SeQure Dx offer?
SeQure Dx offers ONE-seq, SAFER Detection, Guide Profiler, Electroporation Systems, and 4 more products and services.
Who are SeQure Dx's investors?
SeQure Dx has 8 investors. Key investors include MaxCyte, ARE, RiverVest Venture Partners, Mass General Brigham Ventures, and Digitalis Ventures.